Description
A global clinical research study assessing the effectiveness and safety of an Investigational Medication designed to slow the progression of early Alzheimer’s disease.
The ENGAGE study is split into two phases: a placebo-controlled phase, and an optional long-term extension phase.
Related Articles
In the placebo-controlled phase, eligible participants will have a 2-in-3 chance of receiving the investigational medication and a 1-in-3 chance of receiving the placebo.
The post Potential Treatment for Early Onset Alzheimer’s…Ongoing appeared first on Palm Beach Neurological Center.
This post first appeared on News & Announcements Archives - Palm Beach Neurolo, please read the originial post: here
